Symbols / PRPH $0.10 +0.00% ProPhase Labs, Inc.

Healthcare • Diagnostics & Research • United States • PNK
PRPH Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Ted William Karkus
Exch · Country PNK · United States
Market Cap 1.40M
Enterprise Value 9.79M
Income -23.39M
Sales 4.34M
FCF (ttm) 43.01M
Book/sh 0.55
Cash/sh 0.01
Employees 19
Insider 10d —
IPO Apr 04, 1994
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 0.21
PEG —
P/S 0.32
P/B 0.18
P/C —
EV/EBITDA -0.74
EV/Sales 2.25
Quick Ratio 0.03
Current Ratio 0.06
Debt/Eq 245.67
LT Debt/Eq —
EPS (ttm) -2.75
EPS next Y 0.48
EPS Growth —
Revenue Growth -47.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-06-11
Earnings (prior) 2026-06-11
ROA -18.33%
ROE -4.31%
ROIC —
Gross Margin 31.85%
Oper. Margin -7.30%
Profit Margin 0.00%
Shs Outstand 14.02M
Shs Float 13.68M
Insider Own 2.37%
Instit Own 0.07%
Short Float 0.71%
Short Ratio 0.08
Short Interest 30.02K
52W High 6.70
vs 52W High -98.51%
52W Low 0.07
vs 52W Low 42.86%
Beta 0.07
Impl. Vol. 7.25%
Rel Volume 0.00
Avg Volume 156.99K
Volume 349.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.10
Price $0.10
Change 0.00%
About

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.10
Latest analyst target
3. DCF / Fair value
$55.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.10
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-02-21 reit HC Wainwright & Co. Buy → Buy $11
2023-11-10 main HC Wainwright & Co. Buy → Buy $11
2023-08-14 reit HC Wainwright & Co. Buy → Buy $14
2023-06-02 reit HC Wainwright & Co. Buy → Buy $14
2023-05-12 main HC Wainwright & Co. Buy → Buy $14
2023-03-08 reit HC Wainwright & Co. — → Buy $15
2023-02-23 reit HC Wainwright & Co. — → Buy $15
2023-02-16 reit HC Wainwright & Co. — → Buy $15
2023-02-07 reit HC Wainwright & Co. — → Buy $15
2022-11-11 main HC Wainwright & Co. — → Buy $15
2022-05-17 main HC Wainwright & Co. — → Buy $14
2022-03-31 main HC Wainwright & Co. — → Buy $16
2022-01-14 main HC Wainwright & Co. — → Buy $15
2021-12-20 init HC Wainwright & Co. — → Buy $12
2021-10-13 down Dawson James Buy → Neutral —
News
RSS: Latest PRPH news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4.34
-35.82%
6.77
-80.65%
34.98
-71.48%
122.65
Operating Revenue
4.34
-35.82%
6.77
-80.65%
34.98
-71.48%
122.65
Cost Of Revenue
2.96
-57.21%
6.92
-64.38%
19.43
-62.63%
51.99
Reconciled Cost Of Revenue
2.96
-57.21%
6.92
-64.38%
19.43
-62.63%
51.99
Gross Profit
1.38
+1022.67%
-0.15
-100.96%
15.56
-77.98%
70.65
Operating Expense
19.43
-49.50%
38.48
+4.63%
36.78
-21.85%
47.06
Research And Development
0.11
-81.99%
0.59
-57.63%
1.40
+115.03%
0.65
Selling General And Administration
19.32
-48.99%
37.88
+13.29%
33.44
-2.74%
34.38
General And Administrative Expense
19.32
-48.99%
37.88
+13.29%
33.44
-2.74%
34.38
Other Gand A
19.32
-48.99%
37.88
+13.29%
33.44
-2.74%
34.38
Other Operating Expenses
—
—
1.93
-83.93%
12.02
Total Expenses
22.39
-50.68%
45.40
-19.22%
56.20
-43.26%
99.05
Operating Income
-18.05
+53.28%
-38.63
-82.04%
-21.22
-189.93%
23.59
Total Operating Income As Reported
-18.05
+53.28%
-38.63
-82.04%
-21.22
-189.93%
23.59
EBITDA
-11.39
+64.76%
-32.34
-120.56%
-14.66
-151.02%
28.73
Normalized EBITDA
-11.01
+65.60%
-32.00
-118.29%
-14.66
-150.89%
28.81
Reconciled Depreciation
5.06
-23.86%
6.64
+2.67%
6.47
+27.86%
5.06
EBIT
-16.45
+57.79%
-38.98
-84.46%
-21.13
-189.27%
23.67
Total Unusual Items
-0.39
-15.62%
-0.33
0.00
+100.00%
-0.08
Total Unusual Items Excluding Goodwill
-0.39
-15.62%
-0.33
0.00
+100.00%
-0.08
Special Income Charges
-0.60
-79.28%
-0.33
0.00
0.00
Other Special Charges
-0.36
-207.51%
0.33
—
—
Write Off
—
—
—
0.00
Net Income
-14.74
—
—
—
Pretax Income
-23.39
+44.75%
-42.33
-88.99%
-22.40
-197.77%
22.91
Net Non Operating Interest Income Expense
-6.93
-106.96%
-3.35
-181.99%
-1.19
-94.44%
-0.61
Interest Expense Non Operating
6.93
+106.96%
3.35
+164.61%
1.27
+65.71%
0.76
Net Interest Income
-6.93
-106.96%
-3.35
-181.99%
-1.19
-94.44%
-0.61
Interest Expense
6.93
+106.96%
3.35
+164.61%
1.27
+65.71%
0.76
Interest Income Non Operating
—
0.00
-100.00%
0.08
-49.02%
0.15
Interest Income
—
0.00
-100.00%
0.08
-49.02%
0.15
Other Income Expense
1.59
+553.85%
-0.35
-3610.00%
0.01
+113.16%
-0.08
Other Non Operating Income Expenses
2.14
+12011.11%
-0.02
-280.00%
0.01
—
Gain On Sale Of Security
0.21
—
—
-0.08
Tax Provision
0.00
-100.00%
7.20
+219.56%
-6.02
-235.39%
4.45
Tax Rate For Calcs
0.00
-100.00%
0.00
-21.84%
0.00
+38.47%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.07
0.00
+100.00%
-0.01
Net Income Including Noncontrolling Interests
-14.74
+72.37%
-53.36
-217.98%
-16.78
-190.90%
18.46
Net Income From Continuing Operation Net Minority Interest
-23.39
+52.78%
-49.52
-202.35%
-16.38
-188.72%
18.46
Net Income From Continuing And Discontinued Operation
-14.74
+72.37%
-53.36
-217.98%
-16.78
-190.90%
18.46
Net Income Continuous Operations
-23.39
+52.78%
-49.52
-202.35%
-16.38
-188.72%
18.46
Net Income Discontinuous Operations
8.64
+325.16%
-3.84
-854.98%
-0.40
—
Normalized Income
-23.00
+53.31%
-49.26
-200.74%
-16.38
-188.42%
18.52
Net Income Common Stockholders
-14.74
+72.37%
-53.36
-217.98%
-16.78
-190.90%
18.46
Diluted EPS
-1.74
+93.48%
-26.68
-172.24%
-9.80
-196.08%
10.20
Basic EPS
-1.74
+93.48%
-26.68
-172.24%
-9.80
-183.76%
11.70
Basic Average Shares
8.49
+324.45%
2.00
+16.23%
1.72
+8.60%
1.58
Diluted Average Shares
8.49
+324.45%
2.00
+16.23%
1.72
-7.74%
1.87
Diluted NI Availto Com Stockholders
-14.74
+72.37%
-53.36
-217.98%
-16.78
-187.89%
19.09
Average Dilution Earnings
—
—
0.00
-100.00%
0.63
Earnings From Equity Interest
-0.17
0.00
—
—
Gain On Sale Of PPE
-0.95
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
59.87
-5.27%
63.20
-31.25%
91.93
+4.88%
87.65
Current Assets
3.15
-89.72%
30.64
-35.62%
47.59
-21.78%
60.83
Cash Cash Equivalents And Short Term Investments
0.09
-86.73%
0.68
-85.68%
4.74
-72.84%
17.44
Cash And Cash Equivalents
0.09
-86.73%
0.68
-57.86%
1.61
-82.34%
9.11
Other Short Term Investments
—
0.00
-100.00%
3.13
-62.45%
8.33
Receivables
1.54
-92.34%
20.06
-43.99%
35.81
-3.35%
37.05
Accounts Receivable
2.56
-92.67%
34.90
-12.04%
39.68
+5.62%
37.57
Receivables Adjustments Allowances
-1.02
+93.11%
-14.84
-284.14%
-3.86
-23.06%
-3.14
Other Receivables
—
—
—
2.63
Inventory
0.07
-93.88%
1.14
-50.11%
2.29
-42.38%
3.98
Raw Materials
0.00
-99.72%
0.71
-33.61%
1.07
-68.29%
3.38
Work In Process
0.00
-100.00%
0.07
-45.38%
0.12
-84.22%
0.75
Finished Goods
0.07
-81.87%
0.38
-71.59%
1.32
+270.79%
0.36
Prepaid Assets
—
—
—
—
Restricted Cash
—
—
0.54
0.00
Assets Held For Sale Current
0.00
-100.00%
6.14
+120.26%
2.79
—
Other Current Assets
1.45
-44.40%
2.62
+33.76%
1.96
-17.37%
2.37
Total Non Current Assets
56.72
+74.19%
32.56
-26.56%
44.34
+65.36%
26.82
Net PPE
2.03
-82.51%
11.62
-22.05%
14.90
+31.33%
11.35
Gross PPE
5.39
-73.82%
20.60
-1.93%
21.00
+6.14%
19.79
Accumulated Depreciation
-3.36
+62.57%
-8.98
-47.24%
-6.10
+27.74%
-8.44
Properties
0.00
0.00
0.00
0.00
Land And Improvements
—
—
0.35
+0.00%
0.35
Buildings And Improvements
—
—
1.75
+0.98%
1.73
Machinery Furniture Equipment
0.29
-91.51%
3.43
+1.15%
3.39
-56.89%
7.86
Other Properties
5.10
-67.97%
15.93
-7.60%
17.24
+75.07%
9.85
Leases
0.00
-100.00%
1.24
+231.82%
0.37
0.00
Goodwill And Other Intangible Assets
11.13
-25.67%
14.98
-14.71%
17.56
+23.83%
14.18
Goodwill
3.97
-24.14%
5.23
+0.00%
5.23
-8.37%
5.71
Other Intangible Assets
7.17
-26.49%
9.75
-20.94%
12.33
+45.52%
8.47
Investments And Advances
43.49
0.00
—
—
Long Term Equity Investment
43.49
0.00
—
—
Non Current Deferred Assets
—
0.00
-100.00%
7.31
0.00
Non Current Deferred Taxes Assets
—
0.00
-100.00%
7.31
0.00
Non Current Prepaid Assets
0.06
-71.89%
0.22
-73.92%
0.83
+587.60%
0.12
Other Non Current Assets
0.00
-99.97%
5.75
+54.09%
3.73
+220.81%
1.16
Total Liabilities Net Minority Interest
56.36
+0.92%
55.85
+31.27%
42.54
+77.14%
24.02
Current Liabilities
53.08
+65.19%
32.13
+54.07%
20.86
+29.75%
16.07
Payables And Accrued Expenses
43.55
+142.79%
17.94
+29.85%
13.81
+4.45%
13.22
Payables
40.84
+160.07%
15.70
+31.71%
11.92
+18.11%
10.10
Accounts Payable
12.96
-5.51%
13.72
+58.69%
8.64
+46.38%
5.91
Other Payable
27.60
—
—
—
Current Accrued Expenses
2.71
+21.26%
2.23
+18.14%
1.89
-39.58%
3.13
Pensionand Other Post Retirement Benefit Plans Current
—
0.06
-93.90%
1.03
+1966.00%
0.05
Total Tax Payable
0.28
-85.86%
1.99
-39.40%
3.28
-21.74%
4.19
Income Tax Payable
0.28
-85.86%
1.99
-39.40%
3.28
-21.74%
4.19
Current Debt And Capital Lease Obligation
7.98
+21.48%
6.57
+135.16%
2.79
+827.91%
0.30
Current Debt
5.16
+60.74%
3.21
—
—
Other Current Borrowings
5.16
+60.74%
3.21
—
—
Current Capital Lease Obligation
2.82
-15.98%
3.36
+20.34%
2.79
+827.91%
0.30
Current Deferred Liabilities
1.50
-11.60%
1.70
-28.72%
2.38
-4.68%
2.50
Current Deferred Revenue
1.50
-11.60%
1.70
-28.72%
2.38
-4.68%
2.50
Other Current Liabilities
0.05
-99.15%
5.87
+602.63%
0.83
—
Total Non Current Liabilities Net Minority Interest
3.28
-86.16%
23.71
+9.34%
21.69
+173.07%
7.94
Liabilities Heldfor Sale Non Current
0.00
-100.00%
2.92
+0.00%
2.92
—
Long Term Debt And Capital Lease Obligation
0.64
-96.45%
18.00
+14.95%
15.66
+135.22%
6.66
Long Term Debt
—
11.65
+58.88%
7.33
+205.58%
2.40
Long Term Capital Lease Obligation
0.64
-89.94%
6.35
-23.72%
8.33
+95.56%
4.26
Tradeand Other Payables Non Current
2.00
+0.00%
2.00
+0.00%
2.00
0.00
Non Current Deferred Liabilities
0.64
-17.98%
0.78
-28.73%
1.10
-14.26%
1.28
Non Current Deferred Revenue
0.64
-17.98%
0.78
-28.73%
1.10
+3.87%
1.06
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
0.22
Stockholders Equity
3.51
-52.29%
7.35
-85.11%
49.38
-22.39%
63.63
Common Stock Equity
3.51
-52.29%
7.35
-85.11%
49.38
-22.39%
63.63
Capital Stock
0.00
-82.61%
0.02
+27.78%
0.02
+12.50%
0.02
Common Stock
0.00
-82.61%
0.02
+27.78%
0.02
+12.50%
0.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
5.06
+18.12%
4.28
+15.76%
3.70
+7.71%
3.43
Ordinary Shares Number
4.19
+40.19%
2.99
+65.55%
1.80
+11.32%
1.62
Treasury Shares Number
0.87
-32.83%
1.29
-31.68%
1.89
+4.49%
1.81
Additional Paid In Capital
126.48
-2.65%
129.92
+9.46%
118.69
+8.76%
109.14
Retained Earnings
-73.14
-25.25%
-58.39
-1061.13%
-5.03
-142.79%
11.75
Gains Losses Not Affecting Retained Earnings
-0.20
+0.00%
-0.20
+34.00%
-0.30
-139.63%
0.76
Treasury Stock
49.64
-22.43%
64.00
+0.00%
64.00
+10.28%
58.03
Other Equity Adjustments
-0.20
+0.00%
-0.20
+34.00%
-0.30
-139.63%
0.76
Total Equity Gross Minority Interest
3.51
-52.29%
7.35
-85.11%
49.38
-22.39%
63.63
Total Capitalization
3.51
-81.54%
19.00
-66.49%
56.72
-14.11%
66.03
Working Capital
-49.93
-3235.40%
-1.50
-105.60%
26.73
-40.28%
44.76
Invested Capital
8.66
-61.00%
22.21
-60.84%
56.72
-14.11%
66.03
Total Debt
8.62
-64.93%
24.57
+33.14%
18.46
+165.17%
6.96
Net Debt
5.07
-64.28%
14.18
+147.70%
5.72
—
Capital Lease Obligations
3.46
-64.35%
9.71
-12.66%
11.12
+143.90%
4.56
Net Tangible Assets
-7.63
+0.01%
-7.63
-123.97%
31.82
-35.65%
49.45
Tangible Book Value
-7.63
+0.01%
-7.63
-123.97%
31.82
-35.65%
49.45
Interest Payable
0.21
0.00
—
—
Inventories Adjustments Allowances
0.00
+100.00%
-0.01
+96.35%
-0.22
+57.23%
-0.51
Investmentsin Associatesat Cost
43.49
0.00
—
—
Non Current Note Receivables
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-8.34
+52.42%
-17.54
-47.53%
-11.89
-141.64%
28.55
Cash Flow From Continuing Operating Activities
-8.94
+24.25%
-11.80
+3.20%
-12.19
-142.71%
28.55
Cash From Discontinued Operating Activities
0.60
+110.41%
-5.74
-1980.33%
0.30
—
Net Income From Continuing Operations
-23.39
+52.78%
-49.52
-202.35%
-16.38
-188.72%
18.46
Depreciation Amortization Depletion
5.06
-23.86%
6.64
+2.67%
6.47
+27.86%
5.06
Depreciation
5.06
-23.86%
6.64
+2.67%
6.47
+27.86%
5.06
Depreciation And Amortization
5.06
-23.86%
6.64
+2.67%
6.47
+27.86%
5.06
Other Non Cash Items
7.07
+376.30%
1.49
+1025.00%
0.13
+3200.00%
0.00
Pension And Employee Benefit Expense
-1.93
0.00
—
—
Stock Based Compensation
1.89
-47.97%
3.64
+2.88%
3.54
-11.29%
3.99
Provisionand Write Offof Assets
1.00
-90.70%
10.81
+1392.54%
0.72
+186.29%
-0.84
Asset Impairment Charge
1.46
0.00
-100.00%
0.09
-98.52%
6.16
Operating Gains Losses
-1.86
-814.62%
0.26
+677.78%
-0.04
-119.82%
0.23
Gain Loss On Investment Securities
-0.05
-355.56%
0.02
+181.82%
-0.02
-106.21%
0.35
Unrealized Gain Loss On Investment Securities
—
—
0.00
+100.00%
-0.17
Gain Loss On Sale Of PPE
0.95
+1149.45%
-0.09
-295.65%
-0.02
—
Change In Working Capital
-0.18
-101.24%
14.89
+321.50%
-6.72
-54.88%
-4.34
Change In Receivables
0.74
-84.47%
4.74
+867.91%
-0.62
+86.28%
-4.50
Changes In Account Receivables
0.74
-84.47%
4.74
+867.91%
-0.62
+86.28%
-4.50
Change In Inventory
0.31
-76.99%
1.36
+700.00%
0.17
-75.78%
0.70
Change In Prepaid Assets
1.15
+2648.89%
-0.04
+79.17%
-0.22
+64.99%
-0.62
Change In Payables And Accrued Expense
-2.53
-170.04%
3.62
+206.35%
1.18
+35.59%
0.87
Change In Accrued Expense
-0.11
+32.05%
-0.16
+79.74%
-0.77
+13.09%
-0.89
Change In Payable
-2.43
-164.33%
3.77
+93.44%
1.95
+11.04%
1.76
Change In Account Payable
-0.72
-114.25%
5.07
+77.01%
2.86
+355.31%
-1.12
Change In Other Working Capital
-0.34
-105.50%
6.15
+179.91%
-7.70
-1700.00%
0.48
Change In Other Current Assets
0.00
-100.00%
0.85
0.00
+100.00%
-0.56
Change In Other Current Liabilities
0.49
+127.51%
-1.78
-491.45%
0.46
+162.98%
-0.72
Investing Cash Flow
0.92
-62.01%
2.42
+276.92%
-1.37
+34.09%
-2.08
Cash Flow From Continuing Investing Activities
0.12
-95.55%
2.70
+1005.03%
-0.30
+85.65%
-2.08
Cash From Discontinued Investing Activities
0.80
+390.91%
-0.28
+74.32%
-1.07
—
Net PPE Purchase And Sale
0.12
-47.60%
0.23
+397.83%
0.05
-89.82%
0.45
Sale Of PPE
0.12
-47.60%
0.23
+397.83%
0.05
-89.82%
0.45
Capital Expenditure
—
-0.91
+56.53%
-2.08
+46.82%
-3.92
Capital Expenditure Reported
0.00
+100.00%
-0.91
+56.53%
-2.08
+46.82%
-3.92
Net Investment Purchase And Sale
0.00
-100.00%
3.37
-19.01%
4.17
+199.71%
1.39
Purchase Of Investment
—
0.00
+100.00%
-3.82
+43.65%
-6.78
Sale Of Investment
0.00
-100.00%
3.37
-57.75%
7.99
-2.23%
8.17
Net Business Purchase And Sale
—
0.00
+100.00%
-2.43
0.00
Purchase Of Business
—
0.00
+100.00%
-2.90
0.00
Net Other Investing Changes
—
—
0.48
—
Financing Cash Flow
6.84
-51.81%
14.19
+146.40%
5.76
+122.12%
-26.02
Cash Flow From Continuing Financing Activities
6.87
-47.97%
13.21
+366.18%
2.83
+110.89%
-26.02
Net Issuance Payments Of Debt
3.31
-40.98%
5.61
-26.14%
7.60
+207.89%
-7.04
Issuance Of Debt
7.57
-23.20%
9.86
+29.76%
7.60
0.00
Repayment Of Debt
-4.26
-0.28%
-4.25
0.00
+100.00%
-7.04
Long Term Debt Issuance
7.57
-23.20%
9.86
+29.76%
7.60
0.00
Long Term Debt Payments
-4.26
-0.28%
-4.25
0.00
+100.00%
-7.04
Net Long Term Debt Issuance
3.31
-40.98%
5.61
-26.14%
7.60
+207.89%
-7.04
Net Common Stock Issuance
3.56
-53.15%
7.59
+227.27%
-5.97
+38.01%
-9.63
Common Stock Payments
—
0.00
+100.00%
-5.97
+38.01%
-9.63
Common Stock Dividend Paid
—
—
0.00
+100.00%
-9.35
Cash Dividends Paid
—
—
0.00
+100.00%
-9.35
Repurchase Of Capital Stock
—
0.00
+100.00%
-5.97
+38.01%
-9.63
Proceeds From Stock Option Exercised
—
0.00
-100.00%
1.20
0.00
Changes In Cash
-0.59
—
-7.50
—
Beginning Cash Position
0.68
-57.86%
1.61
-82.34%
9.11
+5.21%
8.66
End Cash Position
0.09
-86.73%
0.68
-57.86%
1.61
-82.34%
9.11
Free Cash Flow
-8.34
+54.76%
-18.44
-32.01%
-13.97
-156.72%
24.63
Interest Paid Supplemental Data
1.16
-62.61%
3.10
+233.15%
0.93
+22.15%
0.76
Income Tax Paid Supplemental Data
1.65
+46.09%
1.13
-62.47%
3.00
+76.89%
1.70
Change In Income Tax Payable
-1.71
-32.04%
-1.29
-41.82%
-0.91
-131.65%
2.88
Change In Tax Payable
-1.71
-32.04%
-1.29
-41.82%
-0.91
-131.65%
2.88
Common Stock Issuance
3.56
-53.15%
7.59
0.00
0.00
Issuance Of Capital Stock
3.56
-53.15%
7.59
0.00
0.00
Sale Of Business
—
0.00
-100.00%
0.48
—
Cash From Discontinued Financing Activities
-0.04
-103.58%
0.98
-66.55%
2.92
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category